β-D-2ʹ-DEOXY-2ʹ-α-FLUORO-2ʹ-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR TREATMENT OF DISEASES CAUSED BY HCV Russian patent published in 2022 - IPC A61K31/7076 C07H19/16 A61P31/14 

FIELD: medicine.

SUBSTANCE: present invention relates to a compound selected from compounds of formulas:

, , , or to its pharmaceutically acceptable salt, to a compound of the formula:

or to its pharmaceutically acceptable salt, where the compound is at least 90% free of opposite R-enantiomer for phosphorus, to a compound of the formula:

or to its pharmaceutically acceptable salt, where the compound is at least 90% free of opposite S-enantiomer for phosphorus, to pharmaceutical compositions containing these compounds, to methods for the therapeutic treatment of HCV in a host using these compounds, as well as to the use of these compounds for the treatment of HCV in a host and in the production of a drug for the treatment of HCV in a host.

EFFECT: obtaining compounds for the treatment of HCV.

31 cl, 11 dwg, 7 tbl, 34 ex